RU2017137496A - Средство для лечения множественной миеломы (ММ) - Google Patents
Средство для лечения множественной миеломы (ММ) Download PDFInfo
- Publication number
- RU2017137496A RU2017137496A RU2017137496A RU2017137496A RU2017137496A RU 2017137496 A RU2017137496 A RU 2017137496A RU 2017137496 A RU2017137496 A RU 2017137496A RU 2017137496 A RU2017137496 A RU 2017137496A RU 2017137496 A RU2017137496 A RU 2017137496A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- seq
- sequence
- administered
- region
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Display Devices Of Pinball Game Machines (AREA)
Claims (11)
1. Антитело, специфичное в отношении CD38, содержащее область HCDR1 с последовательностью GFTFSSYYMN (SEQ ID NO: 1) или SYYMN (SEQ ID NO: 2), область HCDR2 с последовательностью GISGDPSNTYYADSVKG (SEQ ID NO: 3), HCDR3 с последовательностью DLPLVYTGFAY (SEQ ID NO: 4), область LCDR1 с последовательностью SGDNLRHYYVY (SEQ ID NO: 5), область LCDR2 с последовательностью GDSKRPS (SEQ ID NO: 6) и область LCDR3 с последовательностью QTYTGGASL (SEQ ID NO: 7), для применения в лечении множественной миеломы, где указанное антитело вводится в дозе, составляющей 8 мг/кг или больше.
2. Антитело по п. 1, где указанное антитело вводится в дозе, составляющей 16 мг/кг или больше.
3. Антитело по п. 1 или 2, где указанное антитело вводится один раз каждые две недели (q2w) в течение по меньшей мере восьми недель.
4. Антитело по любому из предыдущих пунктов, где указанное антитело вводится один раз в неделю (q1w) в течение по меньшей мере восьми недель.
5. Антитело по любому из предыдущих пунктов, где указанное антитело вводится внутривенно.
6. Антитело по любому из предыдущих пунктов, где указанное антитело вводится внутривенно в течение периода, составляющего два часа.
7. Антитело по любому из предыдущих пунктов, где указанное антитело содержит вариабельную область тяжелой цепи с последовательностью
QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQGTLVTVSS (SEQ ID NO: 8) и вариабельную область легкой цепи с последовательностью DIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTGGASLVFGGGTKLTVLGQ (SEQ ID NO: 9).
8. Антитело по любому из предыдущих пунктов, где указанное антитело содержит Fc-область IgG1.
9. Антитело по любому из предыдущих пунктов, где указанное антитело вводится в комбинации с дексаметазоном.
10. Антитело по п. 9, где указанное антитело вводится в комбинации с дексаметазоном, где дексаметазон вводится в дозе, составляющей 20 мг или 40 мг, один раз в неделю (q1W).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15167597.2 | 2015-05-13 | ||
| EP15167597 | 2015-05-13 | ||
| PCT/EP2016/060810 WO2016180958A1 (en) | 2015-05-13 | 2016-05-13 | Treatment for multiple myeloma (mm) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017137496A true RU2017137496A (ru) | 2019-06-13 |
| RU2017137496A3 RU2017137496A3 (ru) | 2019-06-13 |
| RU2723047C2 RU2723047C2 (ru) | 2020-06-08 |
Family
ID=53174925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017137496A RU2723047C2 (ru) | 2015-05-13 | 2016-05-13 | Средство для лечения множественной миеломы (ММ) |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10533057B2 (ru) |
| EP (1) | EP3294769B1 (ru) |
| JP (2) | JP7160533B2 (ru) |
| KR (1) | KR20180008571A (ru) |
| CN (1) | CN107614530A (ru) |
| AU (1) | AU2016260895B2 (ru) |
| CA (1) | CA2984464C (ru) |
| CY (1) | CY1123982T1 (ru) |
| DK (1) | DK3294769T3 (ru) |
| ES (1) | ES2862708T3 (ru) |
| HR (1) | HRP20210552T1 (ru) |
| HU (1) | HUE054271T2 (ru) |
| IL (1) | IL255552B (ru) |
| LT (1) | LT3294769T (ru) |
| MX (1) | MX2017014396A (ru) |
| PL (1) | PL3294769T3 (ru) |
| PT (1) | PT3294769T (ru) |
| RS (1) | RS61668B1 (ru) |
| RU (1) | RU2723047C2 (ru) |
| SG (1) | SG11201708691VA (ru) |
| SI (1) | SI3294769T1 (ru) |
| WO (1) | WO2016180958A1 (ru) |
| ZA (1) | ZA201708386B (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2723047C2 (ru) * | 2015-05-13 | 2020-06-08 | МорфоСис АГ | Средство для лечения множественной миеломы (ММ) |
| CN110144008B (zh) | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
| CN112154156A (zh) * | 2018-03-28 | 2020-12-29 | 武田药品工业株式会社 | 抗cd38抗体的皮下给药 |
| CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
| KR20210104736A (ko) * | 2018-12-14 | 2021-08-25 | 모르포시스 아게 | 항체 제형 |
| WO2020160020A1 (en) * | 2019-01-28 | 2020-08-06 | Sanofi | Methods of treating multiple myeloma |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| CA2329940A1 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| AU2005235811B2 (en) | 2004-02-06 | 2011-11-03 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| EP2511297B1 (en) | 2004-02-06 | 2015-04-08 | MorphoSys AG | Anti-CD38 human antibodies and uses therefor |
| WO2006125640A2 (en) | 2005-05-24 | 2006-11-30 | Morphosys Ag | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
| US7829673B2 (en) | 2005-03-23 | 2010-11-09 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| EP2860192B1 (en) | 2005-10-12 | 2017-09-27 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 |
| AU2007281684C1 (en) * | 2006-08-07 | 2013-12-19 | Abbvie Biotherapeutics Inc. | Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies |
| SI2081595T1 (sl) * | 2006-09-26 | 2019-10-30 | Genmab As | Anti-cd38 plus kortikosteroidi plus ne-kortikosteroidni kemoterapevtik za zdravljenje tumorjev |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| PL2580243T3 (pl) * | 2010-06-09 | 2020-05-18 | Genmab A/S | Przeciwciała przeciwko ludzkiemu CD38 |
| SG188345A1 (en) * | 2010-09-27 | 2013-04-30 | Morphosys Ag | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl |
| US9738933B2 (en) * | 2012-12-05 | 2017-08-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS |
| CN103421115B (zh) * | 2013-09-02 | 2015-06-03 | 东南大学 | 一种cd38纳米抗体及应用 |
| EA201692502A1 (ru) | 2014-06-16 | 2017-09-29 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Лечение миелом |
| MA44560B2 (fr) * | 2014-07-31 | 2021-01-29 | Sanofi Sa | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains |
| WO2016022589A2 (en) * | 2014-08-08 | 2016-02-11 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| JP6707531B2 (ja) | 2014-09-09 | 2020-06-10 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ３８抗体による併用療法 |
| RU2723047C2 (ru) * | 2015-05-13 | 2020-06-08 | МорфоСис АГ | Средство для лечения множественной миеломы (ММ) |
-
2016
- 2016-05-13 RU RU2017137496A patent/RU2723047C2/ru active
- 2016-05-13 PL PL16723349T patent/PL3294769T3/pl unknown
- 2016-05-13 ES ES16723349T patent/ES2862708T3/es active Active
- 2016-05-13 JP JP2017558542A patent/JP7160533B2/ja active Active
- 2016-05-13 KR KR1020177035726A patent/KR20180008571A/ko not_active Application Discontinuation
- 2016-05-13 WO PCT/EP2016/060810 patent/WO2016180958A1/en active Application Filing
- 2016-05-13 PT PT167233493T patent/PT3294769T/pt unknown
- 2016-05-13 US US15/569,495 patent/US10533057B2/en active Active
- 2016-05-13 DK DK16723349.3T patent/DK3294769T3/da active
- 2016-05-13 MX MX2017014396A patent/MX2017014396A/es unknown
- 2016-05-13 RS RS20210419A patent/RS61668B1/sr unknown
- 2016-05-13 LT LTEP16723349.3T patent/LT3294769T/lt unknown
- 2016-05-13 EP EP16723349.3A patent/EP3294769B1/en active Active
- 2016-05-13 SG SG11201708691VA patent/SG11201708691VA/en unknown
- 2016-05-13 CA CA2984464A patent/CA2984464C/en active Active
- 2016-05-13 AU AU2016260895A patent/AU2016260895B2/en active Active
- 2016-05-13 CN CN201680027238.0A patent/CN107614530A/zh active Pending
- 2016-05-13 HU HUE16723349A patent/HUE054271T2/hu unknown
- 2016-05-13 SI SI201631139T patent/SI3294769T1/sl unknown
-
2017
- 2017-11-09 IL IL255552A patent/IL255552B/en unknown
- 2017-12-11 ZA ZA2017/08386A patent/ZA201708386B/en unknown
-
2019
- 2019-11-25 US US16/693,904 patent/US11591406B2/en active Active
-
2021
- 2021-03-30 CY CY20211100276T patent/CY1123982T1/el unknown
- 2021-04-07 HR HRP20210552TT patent/HRP20210552T1/hr unknown
- 2021-05-06 JP JP2021078658A patent/JP2021130668A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180008571A (ko) | 2018-01-24 |
| IL255552A (en) | 2018-01-31 |
| AU2016260895A1 (en) | 2017-11-09 |
| CA2984464C (en) | 2023-10-10 |
| JP7160533B2 (ja) | 2022-10-25 |
| RS61668B1 (sr) | 2021-04-29 |
| HUE054271T2 (hu) | 2021-08-30 |
| LT3294769T (lt) | 2021-04-26 |
| PT3294769T (pt) | 2021-04-13 |
| IL255552B (en) | 2022-01-01 |
| EP3294769A1 (en) | 2018-03-21 |
| SG11201708691VA (en) | 2017-11-29 |
| SI3294769T1 (sl) | 2021-07-30 |
| US20190048091A1 (en) | 2019-02-14 |
| MX2017014396A (es) | 2018-03-23 |
| US20200079871A1 (en) | 2020-03-12 |
| CA2984464A1 (en) | 2016-11-17 |
| HRP20210552T1 (hr) | 2021-05-14 |
| JP2021130668A (ja) | 2021-09-09 |
| EP3294769B1 (en) | 2021-01-13 |
| US10533057B2 (en) | 2020-01-14 |
| AU2016260895B2 (en) | 2021-08-05 |
| PL3294769T3 (pl) | 2021-07-05 |
| US11591406B2 (en) | 2023-02-28 |
| RU2723047C2 (ru) | 2020-06-08 |
| CN107614530A (zh) | 2018-01-19 |
| JP2018515513A (ja) | 2018-06-14 |
| CY1123982T1 (el) | 2022-05-27 |
| ES2862708T3 (es) | 2021-10-07 |
| RU2017137496A3 (ru) | 2019-06-13 |
| WO2016180958A1 (en) | 2016-11-17 |
| DK3294769T3 (da) | 2021-03-08 |
| ZA201708386B (en) | 2019-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) | |
| RU2015110981A (ru) | Комбинации и их применение | |
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| JP2013542194A5 (ru) | ||
| RU2013113933A (ru) | Антитело к cd38 и леналтдомид или бортезомиб для лечения множественной миеломы и nhl | |
| PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
| JP2015514110A5 (ru) | ||
| MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| JP2013542191A5 (ru) | ||
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| FI3110440T3 (fi) | Anti-cd38-vasta-aineita akuutin lymfaattisen leukemian hoitamiseksi | |
| PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| NZ729158A (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
| PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
| PE20141147A1 (es) | Anticuerpos a pcsk9 y usos de los mismos | |
| NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| RU2016138744A (ru) | Антитела, фармацевтические композиции и их применения | |
| JP2015530399A5 (ru) | ||
| HRP20192100T1 (hr) | Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe |